Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2003 1
2005 1
2006 1
2007 2
2008 1
2009 1
2010 2
2011 3
2012 2
2013 6
2014 5
2015 9
2016 8
2017 2
2018 8
2019 5
2020 8
2021 12
2022 6
2023 10
2024 14
2025 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Results by year

Filters applied: . Clear all
Page 1
Trial of Prasinezumab in Early-Stage Parkinson's Disease.
Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, Mollenhauer B, López-Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Gasser T, Poewe W, Ricci B, Boulay A, Vogt A, Boess FG, Dukart J, D'Urso G, Finch R, Zanigni S, Monnet A, Pross N, Hahn A, Svoboda H, Britschgi M, Lipsmeier F, Volkova-Volkmar E, Lindemann M, Dziadek S, Holiga Š, Rukina D, Kustermann T, Kerchner GA, Fontoura P, Umbricht D, Doody R, Nikolcheva T, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. N Engl J Med. 2022 Aug 4;387(5):421-432. doi: 10.1056/NEJMoa2202867. N Engl J Med. 2022. PMID: 35921451 Clinical Trial.
BACKGROUND: Aggregated alpha-synuclein plays an important role in the pathogenesis of Parkinson's disease. The monoclonal antibody prasinezumab, directed at aggregated alpha-synuclein, is being studied for its effect on Parkinson's disease. ...CONCLUSIONS: Prasinezu …
BACKGROUND: Aggregated alpha-synuclein plays an important role in the pathogenesis of Parkinson's disease. The monoclonal antibody pr …
New Advances in Metabolic Syndrome, from Prevention to Treatment: The Role of Diet and Food.
Ambroselli D, Masciulli F, Romano E, Catanzaro G, Besharat ZM, Massari MC, Ferretti E, Migliaccio S, Izzo L, Ritieni A, Grosso M, Formichi C, Dotta F, Frigerio F, Barbiera E, Giusti AM, Ingallina C, Mannina L. Ambroselli D, et al. Nutrients. 2023 Jan 26;15(3):640. doi: 10.3390/nu15030640. Nutrients. 2023. PMID: 36771347 Free PMC article. Review.
This review provides a summary of the last decade of literature related to three principal aspects of MetS: (i) the syndrome's definition and classification, pathophysiology, and treatment approaches; (ii) prediction and diagnosis underlying the biomarkers identified by me …
This review provides a summary of the last decade of literature related to three principal aspects of MetS: (i) the syndrome's defini …
Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.
Pagano G, Trundell D, Simuni T, Pavese N, Marek K, Postuma RB, Shariati N, Monnet A, Moore E, Davies EW, Svoboda H, Pross N, Bonni A, Nikolcheva T; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. NPJ Parkinsons Dis. 2025 Jul 1;11(1):193. doi: 10.1038/s41531-025-01041-9. NPJ Parkinsons Dis. 2025. PMID: 40593721 Free PMC article.
The use of symptomatic medications represents a challenge for clinical trials of novel medicines designed to slow Parkinson's disease progression. A time-to-event (TTE) approach using a defined motor progression milestone may mitigate the confounding effect of symptomatic …
The use of symptomatic medications represents a challenge for clinical trials of novel medicines designed to slow Parkinson's disease …
Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.
Taylor KI, Lipsmeier F, Scelsi MA, Volkova-Volkmar E, Rukina D, Popp W, Lambrecht S, Anzures-Cabrera J, Summers D, Abt M, Monnet A, Kilchenmann T, Schjodt-Eriksen J, Essioux L, Kustermann T, Zago W, Svoboda H, Nikolcheva T, Postuma RB, Pagano G, Lindemann M; PASADENA Investigators; Prasinezumab Study Group. Taylor KI, et al. NPJ Digit Med. 2025 Jun 16;8(1):365. doi: 10.1038/s41746-025-01572-8. NPJ Digit Med. 2025. PMID: 40523921 Free PMC article.
Digital health technology (DHT) tools for Parkinson's disease (PD) e.g., smartphones and wearables were used for remote and frequent measurement of motor signs in the phase 2 PASADENA study of the anti-alpha-synuclein monoclonal antibody prasinezumab. 316 early-stage PD pa …
Digital health technology (DHT) tools for Parkinson's disease (PD) e.g., smartphones and wearables were used for remote and frequent …
Spiritual/Religious Perfectionism Scale in Iran: Psychometric Evaluation.
Besharat MA, Farahani H, Naghipoor M. Besharat MA, et al. J Relig Health. 2021 Oct;60(5):3640-3657. doi: 10.1007/s10943-021-01399-z. Epub 2021 Aug 25. J Relig Health. 2021. PMID: 34432199
Following preliminary psychometric evidence for a 20-item SRPS (Besharat, 2017), the present investigation examined the structure of the SRPS using exploratory factor analysis in study 1 (368 students: 181 men, 187 women) and confirmatory factor analysis in study 2 (384 co …
Following preliminary psychometric evidence for a 20-item SRPS (Besharat, 2017), the present investigation examined the structure of …
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Front Neurol. 2021 Oct 1;12:705407. doi: 10.3389/fneur.2021.705407. eCollection 2021. Front Neurol. 2021. PMID: 34659081 Free PMC article.
Background: Currently available treatments for Parkinson's disease (PD) do not slow clinical progression nor target alpha-synuclein, a key protein associated with the disease. ...Study design assumptions for sample size and study duration were built using a patient cohort …
Background: Currently available treatments for Parkinson's disease (PD) do not slow clinical progression nor target alpha-synuclein, …
Update on Genitourinary Syndrome of Menopause: A Scoping Review of a Tailored Treatment-Based Approach.
Cuccu I, Golia D'Augè T, Firulli I, De Angelis E, Buzzaccarini G, D'Oria O, Besharat AR, Caserta D, Bogani G, Muzii L, Di Donato V, Giannini A. Cuccu I, et al. Life (Basel). 2024 Nov 19;14(11):1504. doi: 10.3390/life14111504. Life (Basel). 2024. PMID: 39598302 Free PMC article.
This scoping review explores the therapeutic strategies available for managing genitourinary syndrome of menopause (GSM), a condition often underdiagnosed and undertreated despite significantly affecting women's quality of life. GSM results from decreased estrogen levels d …
This scoping review explores the therapeutic strategies available for managing genitourinary syndrome of menopause (GSM), a condition often …
MiR-326: Role and significance in brain cancers.
Spinello Z, Besharat ZM, Mainiero F, Rughetti A, Masuelli L, Ferretti E, Catanzaro G. Spinello Z, et al. Noncoding RNA Res. 2025 Feb 25;12:56-64. doi: 10.1016/j.ncrna.2025.02.006. eCollection 2025 Jun. Noncoding RNA Res. 2025. PMID: 40115178 Free PMC article. Review.
In addition, since miR-326 expression can be regulated by other non-coding RNA species, adding a further layer of regulation in the cancer-promoting axis, we discuss this miRNA's role in targeted therapy for brain cancers....
In addition, since miR-326 expression can be regulated by other non-coding RNA species, adding a further layer of regulation in the cancer-p …
Avicenna's View on the Etiologies of Intestinal Obstruction.
Moradi Z, Besharat M, Minaiee B, Aliasl J, Parsa Yekta Z, Nasiri Toosi M. Moradi Z, et al. Iran Red Crescent Med J. 2016 Jan 1;18(2):e20034. doi: 10.5812/ircmj.20034. eCollection 2016 Feb. Iran Red Crescent Med J. 2016. PMID: 27168944 Free PMC article. Review.
EVIDENCE ACQUISITION: The aim of this study was to investigate Avicenna's views on the causes of intestinal obstruction and comparing them to modern medicine views. ...
EVIDENCE ACQUISITION: The aim of this study was to investigate Avicenna's views on the causes of intestinal obstruction and comparing …
106 results